Advanced searches left 3/3

Metformin Polycystic - Crossref

Summarized by Plex Scholar
Last Updated: 05 May 2022

* If you want to update the article please login/register

A decrease in cluster of differentiation 2 expression on natural killer cells is associated with polycystic ovary syndrome but not influenced by metformin in a mouse model

Abstract Problem Natural killer cells from the peripheral blood and spleen are the source from which various tissues restore their immune cell populations. In a PCOS mouse model, we wanted to investigate the distribution of peripheral blood and splenic NK cells and their CD2 and CD94 expression patterns as well as determine whether metformin could reverse these effects. The expressions of CD2 and CD94 were determined on peripheral blood and splenic NK cells, according to flow cytometry. PCOS mice had a low surface-density of CD2 on peripheral blood NK cells, as well as a reduced number of CD2+ splenic NK cells. These changes were not influenced by the Metformin administration's actions; however, it reduced the number of splenic NK cell counts. Conclusions Our results revealed the connection of PCOS with an elevated splenic NK cell number and metformin with an altered expression of CD2 on peripheral blood and splenic NK cells, as well as one of metformin with a reduced splenic NK cell reserve in PCOS conditions.

Source link: https://doi.org/10.1093/biolre/ioac004


Effect of Vitamin D, Metformin on Metabolic Syndrome in Polycystic Ovarian Syndrome Patient

The dose was once daily for about three months and was referred to as '''s'. The first set included 14 patients aged 18 to 30, which divided into two classes, and the first class included 14 patients aged 18 to 30 years old, separated into two classes for the first time before treatment began as and the second class after receiving vitamin D alone 4001. U Similar to the second set, the second class was divided into two classes for the first time, the first class was divided into two classes, and the second class was divided into two classes for the first time, with 14 patients aged from 19 to 30 years old, according to as and the second class after being treated as metformin daily for about 3 months to as G2-B. Metformin also reduced hyperglycemia primarily as a result of reducing glucose production by the liver hepatic gluconeogenesis and the metformin a significant decrease in serum insulin resistance, although metformin has no effect on testosterone levels.

Source link: https://doi.org/10.32947/ajps.v15i1.161


Efficacy of Metformin Therapy in Management of Polycystic Ovary Syndrome

Background: Metformin, according to a previous report, can be helpful clinically in treating polycystic ovary syndrome by lowering hyperinsulinemia. Aim: The aim of this study was to determine the role of metformin in reducing amenorrhea/oligomenorrhea, and anovulation within six months in women with polycystic ovary syndrome and hyperinsulinemia. In the participants, metformin was used to measure hyperinsulinemia and weight loss. The study included 160 women who had the biochemical and medical causes for hyperinsulinemia and PCOS. Serum androgen levels in PCOS are still elevated in PCOS, as well as Prolactin levels, and the LH/FSH ratio may be more than twice as high. Results: Metformin was used for six months, 135 out of 154 women had regular periods, 24 of which were in the ovulation range of luteal progesterone. para ml to 21. 01 micro-U / ml. The average fasting insulin concentration among patients on metformin therapy has decreased from 22. 5 micro-U / ml to 21. 01 micro-U / ml.

Source link: https://doi.org/10.53350/pjmhs22162994

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions